T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
Conditions
- Anatomic Stage III Breast Cancer AJCC v8
- Anatomic Stage IIIA Breast Cancer AJCC v8
- Anatomic Stage IIIB Breast Cancer AJCC v8
- Anatomic Stage IIIC Breast Cancer AJCC v8
- Anatomic Stage IV Breast Cancer AJCC v8
- Estrogen Receptor Positive
- HER2/Neu Negative
- Invasive Breast Carcinoma
- Prognostic Stage III Breast Cancer AJCC v8
- Prognostic Stage IIIA Breast Cancer AJCC v8
- Prognostic Stage IIIB Breast Cancer AJCC v8
- Prognostic Stage IIIC Breast Cancer AJCC v8
- Prognostic Stage IV Breast Cancer AJCC v8
- Recurrent Breast Carcinoma
Interventions
- DRUG: Anastrozole
- DRUG: Exemestane
- DRUG: Fulvestrant
- DRUG: Letrozole
- DRUG: Paclitaxel
- BIOLOGICAL: Talimogene Laherparepvec
- DRUG: Tamoxifen
- DRUG: Nab paclitaxel
- DRUG: Gemcitabine
- DRUG: Carboplatin
Sponsor
University of California, San Francisco
Collaborators